NEW YORK, August 19, 2026, 09:30 EDT
- Pfizer gained 1.41% to close at $27.25 on Tuesday, as the S&P 500 slipped 0.69%.
- CEO Albert Bourla led insider buying totaling approximately $3 million recently.
- The analyst price target of $28.50 represents just a 4.6% potential gain compared to Tuesday’s closing level.
Pfizer Inc. NYSE:PFE shares advanced on Tuesday, outperforming a broader market downturn amid fresh reports of fund reductions. The stock climbed 1.41% to close at $27.25. The S&P 500 slid 0.69%.
The difference is significant since fund disclosures provide a view of past holdings, reflecting earlier quarters rather than real-time transactions on Tuesday. In comparison, recent insider buying gives a more current indication of what Pfizer’s executives chose to acquire following the second-quarter report.
Chief Executive Albert Bourla acquired 38,000 shares on August 12 for $26.34 per share. The transaction, totaling $1,000,920, marked his first open-market purchase since taking on the CEO role. His direct and indirect share ownership increased to 435,555 shares.
| Market signal | Value | Date / context |
|---|---|---|
| PFE close | $27.25 | August 18, 16:00 EDT |
| PFE daily move | +1.41% | Beat S&P 500 by 2.10 points |
| S&P 500 | 7,691.76 | Down 0.69% August 18 |
| Annualized dividend | $1.72 | 6.31% implied yield at closing price |
| Consensus target | $28.50 | 4.6% higher than Tuesday’s close |
On August 5, directors Ronald Blaylock and Mortimer Buckley each made purchases of around $1 million. Alongside Bourla, the trio acquired a total of 114,863 shares, amounting to about $3 million. That same day, Controller Jennifer Damico sold 3,278 shares.
Many institutional-sale reports involve significantly higher share quantities. Four prominent disclosures detail the sale of around 2.53 million shares, valued at close to $68.9 million based on Tuesday’s closing price. This figure is roughly 22 times greater than the number of shares insiders bought in gross terms.
| Disclosed holder action | Shares | Change | Reporting period |
|---|---|---|---|
| HSBC Holdings | Sold 1,821,050 | -10.3% | Fourth quarter |
| Pzena Investment Management | Sold 601,908 | -9.2% | First quarter |
| Meyer Handelman | Sold 58,975 | -5.0% | First quarter |
| Te Ahumairangi Investment Management | Sold 45,057 | -17.6% | Fourth quarter |
| Bourla, Blaylock and Buckley | Bought 114,863 | Approx. $3m | August 5–12 |
The comparison has limitations. The funds disclosed activity for separate periods and may have bought or sold shares since. Insider purchases are more recent but are minimal relative to Pfizer’s approximately 5.7 billion shares outstanding. Neither group of trades signals a sustained pattern of demand.
Performance provides a more rigorous assessment. Pfizer posted second-quarter revenue of $15.03 billion and adjusted earnings per share of $0.77. Profit exceeded analyst expectations of $0.68 by 13%. Non-COVID operational revenue increased by 5%.
| Q2 and guidance measure | Latest | Comparison | Investor read-through |
|---|---|---|---|
| Q2 revenue | $15.03bn | +1% operationally | Limited overall increase |
| Adjusted EPS | $0.77 | $0.68 consensus | 13% above forecasts |
| Launched and acquired products | +18% | Operational growth | Pipeline additions expanding reach |
| 2026 revenue outlook | $60.5bn–$62.5bn | Midpoint raised $0.5bn | Core performance outweighs headwinds |
| 2026 COVID products | About $4bn | Down from about $5bn | Continued decrease for mature products |
| Non-cash impairments | $4.3bn | Reported EPS of -$0.04 | Revision to acquisition valuation |
Interim finance head Cecile Guegan pointed to “18% year-over-year operational revenue growth” achieved by both launched and acquired products. Pfizer further stated it anticipates an extra $2.5 billion in productivity savings from 2027 to 2029. These figures represent company objectives and are not assured. Pfizer Q2 release
This expansion must offset a lengthy period of patent expirations and declining COVID-related sales. The company forecasts higher growth beyond 2028. As a result, the value of its obesity treatments and oncology pipeline outweighs the impact of individual 13F disclosures.
| Analyst / firm | Rating | Target | Latest listed action |
|---|---|---|---|
| Bernstein | Market Perform | $29 | Target reduced from $30, August 7 |
| BMO Capital | Buy | $30 | Target lowered from $34, July 13 |
| Guggenheim | Buy | $35 | Target revised down from $36, July 13 |
| JPMorgan | Hold | $28 | Target decreased from $30, July 8 |
| Cantor Fitzgerald | Hold | $27 | Reaffirmed, June 23 |
Caution persists on Wall Street. MarketBeat reports two sell recommendations, 14 hold ratings, four buys and one strong buy. The consensus price target stands at $28.50, just 4.6% higher than Tuesday’s closing price, with the lowest projection at $25 pointing to an 8.3% drop.
The signal in practice is unclear. Insider buying indicates management’s confidence post-earnings. Tuesday’s relative strength adds further support. However, the modest size of the target gap suggests investors have already factored in much of the short-term recovery.
Risks: Potential drawbacks include pipeline breakdowns, loss of patent protection, changes in drug pricing policies, acquisition-related impairments, and delays in obesity drug progress, which could offset expected savings. On the other hand, positive results in oncology or obesity studies could render existing forecasts overly conservative.
Related articles: NYSE:PFE
Insider confidence, limited target room
Prepared before the August 19 U.S. open
What management bought versus what funds disclosed
Not apples-to-apples: fund reports cover older quarters. Insider purchases occurred August 5–12. Share counts show scale, not current market direction.
Recommendation mix
The hold-heavy mix fits the narrow upside to the average target.
Q2: the portfolio is moving, slowly
Operational growth. Guidance midpoint rose by $500 million after Q2.
Target range after Tuesday's rally
The constructive case
Cash yield plus newer medicines. The indicated dividend yield remains above 6%. Launched and acquired products grew 18% operationally, and management raised the revenue midpoint.
The unresolved case
The bridge beyond 2028. Falling COVID sales, patent losses and $4.3 billion of Q2 impairments keep attention on oncology, obesity assets and cost execution.
